Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly scores FDA okay for Cyramza in liver cancer

Lilly scores FDA okay for Cyramza in liver cancer

Since it first reached the market in 2014, Cyramza has been approved to treat oesophageal cancer, gastric cancer after chemotherapy, non-small cell lung cancer (NSCLC) and colorectal cancer, and has ... result of a switch to immuno-oncology drugs in

Latest news

  • Lilly to withdraw Lartruvo, a first for accelerated approval failures Lilly to withdraw Lartruvo, a first for accelerated approval failures

    market in the US and Europe (other incidences include the FDA withdrawing authorisation for Avastin in breast cancer in 2011). ... In recent times, several immunotherapy treatments have failed confirmatory studies. These include Roche’s Tecentriq and

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    trials being conducted in gastric, colorectal, and non-small cell lung cancer (NSCLC). ... Despite a couple of knockbacks in trials seeking to expand its uses into other indications such as gastric cancer, Kadcyla has become an important part of

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Robin said that studies are now underway or planned for the CD122-biased agonist in small cell lung cancer (SCLC), breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer (TNBC) ... Combination trials in head and neck cancer and

  • Sanofi and Regeneron re-jig immuno-oncology deal Sanofi and Regeneron re-jig immuno-oncology deal

    That candidate is currently in trials for ovarian cancer, but it has potential in cancers expressing the MUC16 biomarker is also frequently expressed in lung, pancreatic, gastric and colorectal cancer.

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and

More from news
Approximately 3 fully matching, plus 68 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... access to its lead candidate FS102 for HER-2 positive patients in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics